Compare MCB & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCB | AKBA |
|---|---|---|
| Founded | 1999 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 906.2M | 729.1M |
| IPO Year | 2017 | 2014 |
| Metric | MCB | AKBA |
|---|---|---|
| Price | $94.25 | $1.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $97.50 | $5.92 |
| AVG Volume (30 Days) | 110.5K | ★ 3.4M |
| Earning Date | 04-21-2026 | 04-12-2026 |
| Dividend Yield | ★ 0.85% | N/A |
| EPS Growth | ★ 11.64 | N/A |
| EPS | ★ 6.62 | 0.03 |
| Revenue | ★ $11,053,000.00 | N/A |
| Revenue This Year | $33.38 | $47.43 |
| Revenue Next Year | $9.32 | $17.65 |
| P/E Ratio | ★ $24.19 | $39.33 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $47.08 | $1.14 |
| 52 Week High | $97.84 | $4.08 |
| Indicator | MCB | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 60.60 | 31.93 |
| Support Level | $92.13 | $1.15 |
| Resistance Level | $96.33 | $1.60 |
| Average True Range (ATR) | 3.10 | 0.09 |
| MACD | -0.57 | -0.02 |
| Stochastic Oscillator | 58.14 | 0.00 |
Metropolitan Bank Holding Corp is a bank holding company. It provides a broad range of business, commercial, and retail banking products and services to small businesses, middle-market enterprises, public entities, and individuals in the New York metropolitan area. The services provided by the company include deposits, trade finance, cash management solutions, savings, electronic banking, cards, and others. The company also provides various lending products such as acquisition loans, construction loans, and lines of credit, for retail, office, hospitality, multifamily, mixed-use, warehouse and distribution, and specialty-use properties. The bank derives its revenue in the form of interest income on loans.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.